Demographic variation across sample populations
| PSC (n=134 overall)* | PBC (n=48) | AIH (n=97) | IBD (n=50) | HC (n=54) | |
|---|---|---|---|---|---|
| Patient age† | 42 (29–59) yrs. | 55 (49–63) | 49 (29–61) | 35 (26–54) | 34 (38–37) |
| Male gender | 83 (62) | 3 (6) | 21 (21) | 31 (62) | 43 (80) |
| UDCA exposure within past 3 months | 96 (72) | 34 (71) | 1 (1) | ||
| Laboratory parameters† | |||||
| Serum AST | 66 (34–100) IU/L | 40 (26–80) IU/L | 31 (23–48) IU/L | ||
| Serum ALT | 61 (34–105) IU/L | 35 (25–77 IU/L | 26 (20–52) IU/L | ||
| Serum ALP (ratio to ULN)‡ | 2.50 (1.80–4.11) | 2.39 (1.43–3.34) | 1.25 (1.11–1.81) | ||
| Bilirubin | 20 (11–48) µmol/L | 13 (7–24) µmol/L | 10 (7–14) µmol/L | ||
| Albumin | 43 (38–45) g/dL | 42 (40–45) g/dL | 44 (41–47) g/dL | ||
| Platelet count | 200 (128–298)×103 cells/mm3 | 247 (153–310)×103 cells/mm3 | 221 (139–283)×103 cells/mm3 | ||
| INR | 1.1 (1.0–1.2) | 1.0 (0.9–1.1) | 1.0 (1.0–1.1) | ||
| Sodium | 141 (139–142) mmol/L | 141 (140–143) mmol/L | 142 (140–144) mmol/L | ||
| Creatinine | 72 (58–82) µmol/L | 64 (58–71) µmol/L | 66 (60–75) µmol/L | ||
| IgG | 14.17 (11.77–17.71) g/L | 14.59 (11.18–17.74) g/L | 14.16 (10.68–16.97) g/L | ||
| ANA-positive | 60 (45) | 21 (49) | 68 (70) | ||
| ASMA-positive | 41 (31) | 11 (26) | 64 (66) | ||
| Cirrhosis† | 95 (71) | 24 (50) | 45 (46) | ||
| Decompensated | 28 | 6 | 4 | ||
| MELD score† | 6 (6–10) | 6 (6–7) | 6 (6–6) | ||
| Child-Turcotte-Pugh score† | |||||
| A | 78 (58) | 35 (73) | 86 (87) | ||
| B | 52 (39) | 10 (21) | 9 (9) | ||
| C | 4 (3) | 1 (2) | 2 (2) | ||
| Clinical events | 56 | 16 | 4 | ||
| Liver transplantation | 44 | 11 | 0 | ||
| Death | 12 | 5 | 4 | ||
Data for categorical variables expressed as number with percentages in parenthesis. Continuous variables expressed as median (IQR).
*Three patients with small-duct PSC.
†At time of sampling.
‡Ratio to upper limit of normal provided, given variation between assay methods over time.
AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ALT, alanine transaminase; ANA, antinuclear antibody; ASMA, anti-smooth muscle antibody; AST, aspartate transaminase; HC, healthy controls; IgG, immunoglobulin G; INR, international normalised ratio; MELD, model for end-stage liver disease score, PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.